氟伐他汀配伍β受体阻滞剂治疗对冠心病并发心力衰竭患者心功能及外周血NF-κB、sST2的影响

Effects of Fluvastatin combined with β-blocker therapy on cardiac function and peripheral blood levels of NF-κB and sST2 in patients with coronary heart disease complicated with heart failure

目的:探究氟伐他汀配伍β受体阻滞剂治疗对冠心病(CHD)并发心力衰竭患者心功能及外周血NF-κB、sST2的影响。方法:选择CHD并发心力衰竭患者90例,随机分为对照组和观察组,各45例。对照组使用阿罗洛尔治疗,观察组使用阿罗洛尔联合氟伐他汀治疗。比较两组患者治疗后的临床疗效。检测并比较两组心功能指标、血脂指标、炎性因子以及血清NF-κB、sST2水平。结果:观察组的有效率显著高于对照组(P<0.05)。治疗后两组心功能指标均得到显著的改善(P<0.05),治疗后观察组的LVEF、LVFS均显著高于对照组,LVEDD、LVESD显著低于对照组(P<0.05)。治疗后两组的血脂指标及炎症因子均显著降低,治疗后观察组hs-CRP、TNF-α、TC、LDL-C均显著低于对照组(P<0.05)。治疗后两组血清NF-κB、sST2均显著降低,治疗后观察组血清NF-κB、sST2均显著低于对照组。两组的不良反应发生情况无显著差异(P<0.05)。结论:氟伐他汀联合β受体阻滞剂可更有效的降低血脂和炎性因子水平,提高对CHD并发心里衰竭患者的临床疗效,并可更有效降低血清NF-κB、sST2,改善预后。

Objective： To investigate the effect of fluvastatin combined with beta blocker therapy on heart function and peripheral blood levels of NF-κB and sST2 in patients with coronary heart disease （CHD） complicated with heart failure.Methods： A total of 90 CHI） patients that suffered from heart failure complication from September 2016 to September 2017 were randomly enrolled and divided into control group and observation group with 45 cases in each group. The control group was treated with Arotinolol, and the observation group was treated with Arotinolol combined with Fluvastatin. The clinical efficacy of the two groups after treatment was compared. Heart function indexes, blood lipid parameters, inflammatory factors, and se rum NF -κB and sST2 levels were detected and compared between the two groups.Flesults：The effective rate of the observation group was significantly higher than that of the control group （P〈0.05）.After treatment, the heart function indicators of both groups were significantly improved. LVEF and LVFS were significantly higher in the observation group than those in the con trol group, but LVEDD and LVESD were significantly lower than those in the control group （P 〈0.05）.After treatment, blood lipids and inflammatory factors in both groups were significantly reduced, hs CRP, TNF-α, TC, and LDL-C in the observation group were significantly lower than those in the control group （P 〈0.05）.After treatment, both serum NF-κB and sST2 levels wcrc significantly decreased,serum NF -κB and sST2 wcrc significantly lower in the observation group than those in the control group.Thcrc was no significant difference in the incidence of adverse reactions between the two groups （P〉0.05）.Conclusion： Fluvastatin combined with β-blockers can reduce the levels of blood lipids and inflammatory factorsmorc effectively, thus improvc the clinical efficacy of CHD in paticnts complicatcd with heart failure. This thcrapy can reduce serum NF-κB, sST2 levels more effectively too indicating it can improve prognosis of the disease.